DOI QR코드

DOI QR Code

Colorectal Cancer Screening in High-risk Populations: a Survey of Cognition among Medical Professionals in Jiangsu, China

  • Chen, Yao-Sheng (Department of Gastroenterology, Yangzhou NO.1 People's Hospital) ;
  • Xu, Song-Xin (Department of Gastroenterology, Yangzhou NO.1 People's Hospital) ;
  • Ding, Yan-Bing (Department of Gastroenterology, Yangzhou NO.1 People's Hospital) ;
  • Huang, Xin-En (Department of Gastroenterology, Clinical Medical College of Yangzhou University) ;
  • Deng, Bin (Department of Gastroenterology, Yangzhou NO.1 People's Hospital) ;
  • Gao, Xue-Feng (Department of Gastroenterology, Yangzhou NO.1 People's Hospital) ;
  • Wu, Da-Cheng (Department of Gastroenterology, Yangzhou NO.1 People's Hospital)
  • Published : 2013.11.30

Abstract

To investigate the cognition of medical professionals when following screening guidelines for colorectal cancer (CRC) and barriers to CRC screening. Between February 2012 and December 2012, an anonymous survey with 19-questions based on several CRC screening guidelines was randomly administered to gastroenterologists, oncologists, general surgeons, and general practitioners in Jiangsu, a developed area in China where the incidence of CRC is relatively high. The average cognitive score was 26.4% among 924 respondents. Gastroenterologists and oncologists had higher scores compared with others (p<0.01 and p<0.01, respectively); doctor of medicine (M.D.) with or without doctor of philosophy (Ph.D.) or holders with bachelor of medical science (BMS) achieved higher scores than other lower degree holders (P<0.05). More importantly, doctors who finished CRC related education in the past year achieved higher scores than the others (p<0.001). The most commonly listed barriers to referring high-risk patients for CRC screening were "anxiety about colonoscopy without anesthesia", "lack of awareness of the current guidelines" and "lack of insurance reimbursement". Lack of cognition was detected among doctors when following CRC screening guidelines for high-risk populations. Educational programs should be recommended to improve their cognition and reduce barriers to CRC screening.

Keywords

High-risk;colorectal cancer;family history;screening;survey

References

  1. Amir Q, Thomas DD, Robert HH, et al (2012). Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med, 156, 378-6. https://doi.org/10.7326/0003-4819-156-5-201203060-00010
  2. Boolchand V, Olds G, Singh J, et al (2006). Colorectal screening after polypectomy: a national survey study of primary care physicians. Ann Intern Med, 145, 654-9. https://doi.org/10.7326/0003-4819-145-9-200611070-00007
  3. Brawarsky P, Brooks DR, Mucci LA, et al (2004). Effect of physician recommendation and patient adherence on rates of colorectal cancer testing. Cancer Detect Prev, 28, 260-8. https://doi.org/10.1016/j.cdp.2004.04.006
  4. Burt RW, Barthel JS, Dunn KB, et al (2008). NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw, 8, 8-61.
  5. Butterly LF, Goodrich M, Onega T, et al (2010). Improving the quality of colorectal cancer screening: assessment of familial risk. Dig Dis Sci, 55, 754-60. https://doi.org/10.1007/s10620-009-1058-z
  6. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening among adults aged 50-75 years-United States, 2008. MMWR Morb Mortal Wkly Rep, 59, 808-12.
  7. Deng QQ, Huang XE, Ye LH, et al (2013). Phase II trial of $Loubo^{(R)}$ (Lobaplatin) and pemetrexed for patients with metastatic breast cancer not responding to anthracycline or taxanes. Asian Pac J Cancer Prev, 14, 413-7. https://doi.org/10.7314/APJCP.2013.14.1.413
  8. Dulai GS, Farmer MM, Ganz PA, et al (2004). Primary care provider perceptions of barriers to and facilitators of colorectal cancer screening in a managed care setting. Cancer, 100, 1843-52. https://doi.org/10.1002/cncr.20209
  9. Fang J (2011). The guideline for early diagnosis, treatment and integrated prevention of colorectal cancer in China. Gastroenterology [Chinese].
  10. Gao LL, Huang XE, Zhang Q, et al (2011). A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China, final results of a phase II clinical trial. Asian Pac J Cancer Prev, 12, 77-80.
  11. Gong P, Huang XE, Chen CY, et al (2012). Comparison of complications of peripherally inserted central catheters with ultrasound guidance or conventional methods in cancer patients. Asian Pac J Cancer Prev, 13, 1873-5. https://doi.org/10.7314/APJCP.2012.13.5.1873
  12. Gu M, Li SY, Huang XE, et al (2013). A phase II study on continuous infusional paclitaxel and 5-Fu as first-line chemotherapy for patients with advanced esophageal cancer. Asian Pac J Cancer Prev, 13, 5587-91.
  13. Guerra CE, Schwartz JS, Armstrong K, et al (2007). Barriers of and facilitators to physician recommendation of colorectal cancer screening. J Gen Intern Med, 22, 1681-8. https://doi.org/10.1007/s11606-007-0396-9
  14. Huang XE, Li CG, Li Y, et al (2011). Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial. Asian Pac J Cancer Prev, 12, 2797-800.
  15. Huang XE, Wei GL, Huo JG, et al (2013). Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites. Asian Pac J Cancer Prev, 14, 2611-4. https://doi.org/10.7314/APJCP.2013.14.4.2611
  16. Jenn HK, FRACP, Rupert WL, et al (2012). Knowledge of, attitudes toward, and barriers to participation of colorectal cancer screening tests in the Asia-Pacific region, a multicenter study. Gastrointest Endosc, 76, 126-35. https://doi.org/10.1016/j.gie.2012.03.168
  17. Jiang Y, Huang XE, Yan PW, et al (2010). Validation of treatment efficacy of a computer-assisted program for breast cancer patients receiving postoperative adjuvant chemotherapy.Asian Pac J Cancer Prev, 11, 1059-62.
  18. Jones RM, Devers KJ, Kuzel AJ, et al (2010). Patient-reported barriers to colorectal cancer screening, a mixed-methods analysis. Am J Prev Med, 38, 508-16. https://doi.org/10.1016/j.amepre.2010.01.021
  19. Klabunde CN, Frame PS, Meadow A, et al (2003). A national survey of primary care physicians’ colorectal cancer screening recommendations and practices. Prev Med, 36, 352-62. https://doi.org/10.1016/S0091-7435(02)00066-X
  20. Klabunde CN, Lanier D, Nadel MR, et al (2009). Colorectal cancer screening by primary care physicians: recommendations and practices, 2006-2007. Am J Prev Med, 37, 8-16. https://doi.org/10.1016/j.amepre.2009.03.008
  21. Klabunde CN, Vernon SW, Nadel MR, et al (2005). Barriers to colorectal cancer screening, a comparison of reports from primary care physicians and average-risk adults. Med Care, 43, 939-44. https://doi.org/10.1097/01.mlr.0000173599.67470.ba
  22. Kilickap S, Arslan C, Rama D, Yalcin S (2012). Screening colonoscopy participation in Turkish colorectal cancer patients and their first degree relatives. Asian Pac J Cancer Prev, 13, 2829-32. https://doi.org/10.7314/APJCP.2012.13.6.2829
  23. Levin B, Lieberman DA, McFarland B, et al (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology, 134, 1570-95. https://doi.org/10.1053/j.gastro.2008.02.002
  24. Li CG, Huang XE, Li Y, Lu YY (2011). Clinical observations on safety and efficacy of $OxyContin^{(R)}$ administered by rectal route in treating cancer related pain. Asian Pac J Cancer Prev, 12, 2477-8.
  25. Li CG, Huang XE, Xu L, et al (2012). Clinical application of serum tumor associated material (TAM) from non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 301-4. https://doi.org/10.7314/APJCP.2012.13.1.301
  26. Li CG, Huang XE,Li Y, et al (2011). Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer. Asian Pac J Cancer Prev, 12, 487-90.
  27. Lieberman DA, Rex DK, Winawer SJ, et al (2012). Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology, 143, 844-57. https://doi.org/10.1053/j.gastro.2012.06.001
  28. Lin YH, Kao CC (2012). Factors influencing colorectal cancer screening in rural southern Taiwan. Cancer Nursing, 36, 284-91.
  29. Li Y, Yan PW, Huang XE, et al (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-09.
  30. Liu J, Huang XE, Tian GY, et al (2013). Phase II study on safety and efficacy of $Yadanzi^{(R)}$ (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Asian Pac J Cancer Prev, 14, 2009-12. https://doi.org/10.7314/APJCP.2013.14.3.2009
  31. Liu W, Li SY, Huang XE, et al (2012). Inhibition of tumor growth in vitro by a combination of extracts from rosa roxburghii tratt and fagopyrum cymosum. Asian Pac J Cancer Prev, 13, 2409-14. https://doi.org/10.7314/APJCP.2012.13.5.2409
  32. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  33. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. https://doi.org/10.7314/APJCP.2013.14.3.2005
  34. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 2, 533-43 https://doi.org/10.1016/S1470-2045(01)00486-7
  35. Rex DK, Johnson DA, Anderson JC, et al (2009). American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol, 104, 739-50. https://doi.org/10.1038/ajg.2009.104
  36. Schroy PC, Barrison AF, Ling BS, Wilson S, Geller AC. (2002). Family history and colorectal cancer screening, a survey of physician knowledge and practice patterns. Am J Gastroenterol, 97, 1031-6. https://doi.org/10.1111/j.1572-0241.2002.05624.x
  37. Shu J, Li CG, Liu YC, et al (2012).Comparison of Serum Tumor Associated Material (TAM) with Conventional Biomarkers in Cancer Patients. Asian Pac J Cancer Prev, 13, 2399-403. https://doi.org/10.7314/APJCP.2012.13.5.2399
  38. Sun MQ, Meng AF, Huang XE, et al (2013). Comparison of psychological influence on breast cancer patients between breast-conserving surgery and modified radical mastectomy. Asian Pac J Cancer Prev, 14, 149-52. https://doi.org/10.7314/APJCP.2013.14.1.149
  39. Sung JJ, Lau JY, Goh KL, et a1 (2005). Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncel, 6, 871-6. https://doi.org/10.1016/S1470-2045(05)70422-8
  40. Taylor V, Lessler D, Mertens K, et al (2003). Colorectal cancer screening among African Americans, the importance of physician recommendation. J Natl Med Assoc, 95, 806-12.
  41. White PM, Sahu M, Poles MA, Francois F (2012). Colorectal cancer screening of high-risk populations: A national survey of physicians. BMC Res Notes, 5, 64. https://doi.org/10.1186/1756-0500-5-64
  42. Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. https://doi.org/10.7314/APJCP.2013.14.3.2019
  43. Xu HX, Huang XE, Li Y, et al (2011). A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. Asian Pac J Cancer Prev, 12, 2233-6.
  44. Xu HX, Huang XE, Qian ZY, et al (2011). Clinical observation of Endostar combined with chemotherapy in advanced colorectal cancer patients. Asian Pac J Cancer Prev, 12, 3087-90.
  45. Xu JW, Li CG, Huang XE, et al (2011). Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced lung adenocarcinoma cases. Asian Pac J Cancer Prev, 12, 985-7.
  46. Xu T, Xu ZC, Zou Q, Yu B, Huang XE (2012). P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. Asian Pac J Cancer Prev, 13, 2349-54. https://doi.org/10.7314/APJCP.2012.13.5.2349
  47. Xu X, Wang L, Xu HQ, Huang XE, et al (2013). Clinical comparison between paclitaxel liposome ($Lipusu^{(R)}$) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev, 14, 2591-4. https://doi.org/10.7314/APJCP.2013.14.4.2591
  48. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pac J Cancer Prev, 11, 1115-8.
  49. Yan PW, Huang XE, Yan F, et al (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
  50. Yin HT, Tian QZ, Guan L,n vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-6. https://doi.org/10.7314/APJCP.2013.14.3.1703
  51. Yin HT, Zhang DG, Wu XL, Huang XE, Chen G (2013). In vivo evaluation of curcumin-loaded nanoparticles in a A549 xenograft mice model. Asian Pac J Cancer Prev, 14, 409-12. https://doi.org/10.7314/APJCP.2013.14.1.409
  52. Yu DS, Huang XE, Zhou JN, et al (2012). Comparative study on the value of anal preserving surgery for aged people with low rectal carcinoma in Jiangsu, China. Asian Pac J Cancer Prev, 13, 2339-40. https://doi.org/10.7314/APJCP.2012.13.5.2339
  53. Zhan YP, Huang XE, Cao J, Clinical study on safety and efficacy of Qinin (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 4773-6. https://doi.org/10.7314/APJCP.2012.13.9.4773
  54. Zhan YP, Huang XE, Cao J (2012). Clinical safety and efficacy of Kanglaite (Coix Seed Oil) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pac J Cancer Prev, 13, 5319-21. https://doi.org/10.7314/APJCP.2012.13.10.5319
  55. Zhang LQ, Huang XE, Wang J (2011). The cyclin D1 G870A polymorphism and colorectal cancer susceptibility: a meta-analysis of 20 populations. Asian Pac J Cancer Prev, 12, 81-5.
  56. Zhang XZ, Huang XE, Xu YL, et al (2012). A Phase II Study on Voriconazole in Treating Chinese Patients with Malignant Hematological Disorder and Invasive Aspergillosis. Asian Pac J Cancer Prev, 13, 2415-8. https://doi.org/10.7314/APJCP.2012.13.5.2415
  57. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

Cited by

  1. Implementation of Screening Colonoscopy amongst First-Degree Relatives of Patients with Colorectal Cancer in Turkey: a Cross-Sectional Questionnaire Based Survey vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5523
  2. A Predictive Model for Evaluating Responsiveness to Pemetrexed Treatment in Patients with Advanced Colorectal Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5941
  3. Survival of Colorectal Cancer Patients in the Presence of Competing-Risk vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6253
  4. Prevalence and Characteristics of Colorectal Polyps in Symptomatic and Asymptomatic Iranian Patients Undergoing Colonoscopy from 2009-2013 vol.15, pp.22, 2014, https://doi.org/10.7314/APJCP.2014.15.22.9933
  5. A Systemic Analysis of S-1 Regimens for Treatment of Patients with Colon Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2191
  6. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  7. Stressful Life Events and Risk of Colorectal Cancer: A Case-Control Study of Iran vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2403
  8. Poor Knowledge of Colorectal Cancer in Brunei Darussalam vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3927